Vesicular monoamine transporter 2 (VMAT2) is an integral membrane protein that packages monoamines, including dopamine, norepinephrine, serotonin, and histamine, into synaptic vesicles. VMAT2 is normally expressed in sympathetic, enteric, and central nervous system neurons and in neuroendocrine cells. Although VMAT2 immunoreactivity was originally reported in a wide range of neuroendocrine neoplasms (NENs), its diagnostic value has been largely overlooked in recent practice due to reliance on established markers such as chromogranin A (CgA), synaptophysin (SYP), and the transcription factors ISLET1 and INSM1. To reassess the relevance of VMAT2, we evaluated its expression relative to CgA, SYP, ISLET1, and INSM1 in 60 consecutively diagnosed NENs from diverse anatomic sites and tumor grades. VMAT2 was positive in 37 of 39 (95%) well-differentiated neuroendocrine tumors (NETs; grades 1–3), in all adrenal paragangliomas (7 of 7) and in one medullary thyroid carcinoma, showing sensitivity comparable to CgA and INSM1 and slightly lower than SYP. VMAT2 was detected in 7 of 12 (58%) neuroendocrine carcinomas. Sensitivity was highest in small-intestinal and gastric NETs and more variable in pancreatic NETs. These results support VMAT2 as a robust, differentiation-linked neuroendocrine marker whose inclusion in modern immunohistochemical panels may improve diagnostic accuracy:
JuhlinCCZedeniusJHöögA.Clinical routine application of the second-generation neuroendocrine markers ISL1, INSM1, and secretagogin in neuroendocrine neoplasia: staining outcomes and potential clues for determining tumor origin. Endocr Pathol. 2020;31(4):401–10. doi:10.1007/s12022-020-09645-y.
3.
WiedenmannBFrankeWWKuhnCMollRGouldVE.Synaptophysin: a marker protein for neuroendocrine cells and neoplasms. Proc Natl Acad Sci U S A. 1986;83(10):3500–4. doi:10.1073/pnas.83.10.3500.
4.
LloydRVBlaivasMWilsonBS.Distribution of chromogranin and S100 protein in normal and abnormal adrenal medullary tissues. Arch Pathol Lab Med. 1985;109(7):633–5.
5.
RindiGMeteOUccellaSBasturkOLa RosaSBrosensLAAEzzatSde HerderWWKlimstraDSPapottiMAsaSL.Overview of the 2022 WHO classification of neuroendocrine neoplasms. Endocr Pathol. 2022;33(1):115–54. doi:10.1007/s12022-022-09708-2.
6.
MukhopadhyaySDermawanJKLaniganCPFarverCF.Insulinoma-associated protein 1 (INSM1) is a sensitive and highly specific marker of neuroendocrine differentiation in primary lung neoplasms: an immunohistochemical study of 345 cases, including 292 whole-tissue sections. Mod Pathol. 2019;32(1):100–9. doi:10.1038/s41379-018-0122-7.
7.
SchmittAMRinikerFAnlaufMSchmidSSoltermannAMochHHeitzPUKlöppelGKomminothPPerrenA.Islet 1 (Isl1) expression is a reliable marker for pancreatic endocrine tumors and their metastases. Am J Surg Pathol. 2008;32(3):420–5. doi:10.1097/PAS.0b013e318158a397.
8.
RosenbaumJNGuoZBausRMWernerHRehrauerWMLloydRV.INSM1: a novel immunohistochemical and molecular marker for neuroendocrine and neuroepithelial neoplasms. Am J Clin Pathol. 2015;144(4):579–91. doi:10.1309/AJCPGZWXXBSNL4VD.
9.
LiloMTChenYLeBlancRE.INSM1 is more sensitive and interpretable than conventional immunohistochemical stains used to diagnose merkel cell carcinoma. Am J Surg Pathol. 2018;42(11):1541–8. doi:10.1097/PAS.0000000000001136.
10.
RooperLMSharmaRLiQKIlleiPBWestraWH.INSM1 demonstrates superior performance to the individual and combined use of synaptophysin, chromogranin and CD56 for diagnosing neuroendocrine tumors of the thoracic cavity. Am J Surg Pathol. 2017;41(11):1561–9. doi:10.1097/PAS.0000000000000916.
11.
StaafJTranLSöderlundLNodinBJirströmKVidarsdottirHPlanckMMattssonJSMBotlingJMickePBrunnströmH.Diagnostic value of insulinoma-associated protein 1 (INSM1) and comparison with established neuroendocrine markers in pulmonary cancers. Arch Pathol Lab Med. 2020;144(9):1075–85. doi:10.5858/arpa.2019-0250-OA.
12.
TanigawaMNakayamaMTairaTHattoriSMiharaYKondoRKusanoHNakamuraKAbeYIshidaYOkabeYHisakaTOkudaKFujinoKItoTKawaharaANaitoYYamaguchiRAkibaJAkagiYYanoH.Insulinoma-associated protein 1 (INSM1) is a useful marker for pancreatic neuroendocrine tumor. Med Mol Morphol. 2018;51(1):32–40. doi:10.1007/s00795-017-0167-6.
13.
GrahamRPShresthaBCaronBLSmyrkTCGroggKLLloydRVZhangL.Islet-1 is a sensitive but not entirely specific marker for pancreatic neuroendocrine neoplasms and their metastases. Am J Surg Pathol. 2013;37(3):399–405. doi:10.1097/PAS.0b013e31826f042c.
14.
KooJZhouXMoschianoEDe Peralta-VenturinaMMertensRBDhallD.The immunohistochemical expression of islet 1 and PAX8 by rectal neuroendocrine tumors should be taken into account in the differential diagnosis of metastatic neuroendocrine tumors of unknown primary origin. Endocr Pathol. 2013;24(4):184–90. doi:10.1007/s12022-013-9264-9.
15.
MohantySKTiwariABhardwajNChuangFKimELugoHYuanXDiffalhaSAPeralta-VenturinaMBalzerBDhallD.Positivity for SATB2 distinguishes Islet1 positive rectal neuroendocrine tumours from pancreaticoduodenal neuroendocrine tumours. J Clin Pathol. 2021;74(9):582–8. doi:10.1136/jclinpath-2020-206645.
16.
AnlaufMEisseleRSchäferMKEidenLEArnoldRPauserUKlöppelGWeiheE.Expression of the two isoforms of the vesicular monoamine transporter (VMAT1 and VMAT2) in the endocrine pancreas and pancreatic endocrine tumors. J Histochem Cytochem. 2003;51(8):1027–40. doi:10.1177/002215540305100806.
17.
JakobsenAMAnderssonPSaglikGAnderssonEKölbyLEricksonJDForssell-AronssonEWängbergBAhlmanHNilssonO.Differential expression of vesicular monoamine transporter (VMAT) 1 and 2 in gastrointestinal endocrine tumours. J Pathol. 2001;195(4):463–72. doi:10.1002/path.973.
18.
WeiheESchäferMKEricksonJDEidenLE.Localization of vesicular monoamine transporter isoforms (VMAT1 and VMAT2) to endocrine cells and neurons in rat. J Mol Neurosci. 1994;5(3):149–64. doi:10.1007/BF02736730.
19.
EisseleRAnlaufMSchäferMKEidenLEArnoldRWeiheE.Expression of vesicular monoamine transporters in endocrine hyperplasia and endocrine tumors of the oxyntic stomach. Digestion. 1999;60(5):428–39. doi:10.1159/000007688.
20.
RindiGPaolottiDFioccaRWiedenmannBHenryJPSolciaE.Vesicular monoamine transporter 2 as a marker of gastric enterochromaffin-like cell tumors. Virchows Arch. 2000;436(3):217–3. doi:10.1007/s004280050033.
21.
DuanKMeteO.Algorithmic approach to neuroendocrine tumors in targeted biopsies: practical applications of immunohistochemical markers. Cancer Cytopathol. 2016;124(12):871–84. doi:10.1002/cncy.21765.
22.
EricksonJDSchaferMKBonnerTIEidenLEWeiheE.Distinct pharmacological properties and distribution in neurons and endocrine cells of two isoforms of the human vesicular monoamine transporter. Proc Natl Acad Sci U S A. 1996;93(10):5166–71. doi:10.1073/pnas.93.10.5166.
23.
UccellaSCeruttiRVigettiDFurlanDOldriniRCarnevaliIPelosiGLa RosaSPassiACapellaC.Histidine decarboxylase, DOPA decarboxylase, and vesicular monoamine transporter 2 expression in neuroendocrine tumors: immunohistochemical study and gene expression analysis. J Histochem Cytochem. 2006;54(8):863–75. doi:10.1369/jhc.5A6770.2006.
